Review: Amiodarone reduces risk for sudden cardiac death but not all-cause mortality in cardiomyopathy
Authors: Munther K. Homoud
Journal: Annals of Internal Medicine (2009)

ACP Journal Club20 October 2009Review: Amiodarone reduces risk for sudden cardiac death but not all-cause mortality in cardiomyopathyMunther K. Homoud, MD, FACP, FACC, FHRSMunther K. Homoud, MD, FACP, FACC, FHRSTufts Medical Center, Boston, Massachusetts, USA (M.K.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-8-200910200-02013 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationPiccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30:1245-53. https://pubmed.ncbi.nlm.nih.gov/19336434Clinical Impact RatingsCardiology: References1 Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet. 1997;350:1417-24. [PMID: 9371164] Google Scholar2 Bardy GH, Lee KL, Mark DB, et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37. [PMID: 15659722] Google Scholar3 Daubert JP, Zareba W, Cannom DS, et al; MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol. 2008;51:1357-65. [PMID: 18387436] Google Scholar4 Connolly SJ, Dorian P, Roberts RS, et al; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295:165-71. [PMID: 16403928] Google Scholar5 Epstein AE, DiMarco JP, Ellenbogen KA, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51:e1-62. [PMID: 18498951] Google Scholar Author, Article, and Disclosure InformationAffiliations: Tufts Medical Center, Boston, Massachusetts, USA (M.K.H.)This article was published at Annals.org on 6 October 2009. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 20 October 2009Volume 151, Issue 8Page: JC4-13KeywordsAdverse reactionsCardiomyopathiesCardiovascular diseasesHeartHeart failureMortalityShockSudden cardiac deathThyroidToxicity ePublished: 20 October 2009 Issue Published: 20 October 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...